MichBio is a non-profit association representing more than 600 bioscience companies, universities and academic institutions dedicated to advancing Michigan's bioscience industry. MichBio is the state's leading advocate for the bio-industry. MichBio fosters an environment that educates the public and policy makers, influences public policy and advances the economic interests of its member companies and the industry as a whole.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Diagnostics

EVONETIX GRANTED PATENT FOR TECHNOLOGY ENABLING THERMALLY-CONTROLLED DNA SYNTHESIS

evonetix | April 04, 2022

news image

EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it has been granted patent EP3551331B1 in Europe for its proprietary thermal control technology for DNA synthesis, as well as the design and manufacture of its silicon chips. This patent extends Evonetix’s IP portfolio and is a key step in the Company’s strategy to develop a benchtop DNA synthesis platform, to change how DNA is accessed, made, and u...

Read More

BOLDER BIOTECHNOLOGY ANNOUNCES POSITIVE PRECLINICAL DATA FOR USE OF BBT-032 TO INHIBIT GROWTH OF THE SARS-COV-2 VIRUS

PR Newswire | August 26, 2020

news image

Bolder BioTechnology, Inc. announced today that preclinical studies have shown that its proprietary long-acting interferon beta analog, BBT-032, strongly inhibits growth of the SARS-CoV-2 virus in culture at concentrations expected to be readily achievable in patients. SARS-CoV-2 is the coronavirus responsible for the Covid-19 pandemic.Based upon these promising results, Bolder BioTechnology intends to file an Investigational New Drug Application with the U.S. Food and Drug Administration ...

Read More

AI

BIOMARIN AND DEEP GENOMICS TO COLLABORATE ON ADVANCING PROGRAMS IDENTIFIED USING ARTIFICIAL INTELLIGENCE

BioMarin | November 18, 2020

news image

BioMarin Pharmaceutical Inc. and Deep Genomics declares that the organizations have gone into a preclinical collaboration that will use Deep Genomics' artificial intelligence drug discovery platform (The AI Workbench) to distinguish oligonucleotide drug applicants in four uncommon sickness signs with high neglected need. Deep Genomics will get an undisclosed forthright installment and is qualified to get improvement achievements as a piece of the coordinated effort. BioMarin will get an elit...

Read More

Medical

SALIPRO BIOTECH OBTAINS GRANTED PATENTS IN THE UNITED STATES AND CHINA FOR DIRECT EXTRACTION OF MEMBRANE PROTEINS AND LIBRARY GENERATION

Salipro Biotech | September 08, 2022

news image

Salipro Biotech AB, a Swedish biotech company with a leading technology platform for the stabilization of membrane proteins for drug development, announced today that its patent entitled "Saposin lipoprotein particles and libraries from crude membranes" has been issued by both the U.S. Patent and Trademark Office and by the China National Intellectual Property Administration. The patents cover the company's novel method of direct extraction of membrane proteins from cells or crude ...

Read More
news image

Diagnostics

EVONETIX GRANTED PATENT FOR TECHNOLOGY ENABLING THERMALLY-CONTROLLED DNA SYNTHESIS

evonetix | April 04, 2022

EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it has been granted patent EP3551331B1 in Europe for its proprietary thermal control technology for DNA synthesis, as well as the design and manufacture of its silicon chips. This patent extends Evonetix’s IP portfolio and is a key step in the Company’s strategy to develop a benchtop DNA synthesis platform, to change how DNA is accessed, made, and u...

Read More
news image

BOLDER BIOTECHNOLOGY ANNOUNCES POSITIVE PRECLINICAL DATA FOR USE OF BBT-032 TO INHIBIT GROWTH OF THE SARS-COV-2 VIRUS

PR Newswire | August 26, 2020

Bolder BioTechnology, Inc. announced today that preclinical studies have shown that its proprietary long-acting interferon beta analog, BBT-032, strongly inhibits growth of the SARS-CoV-2 virus in culture at concentrations expected to be readily achievable in patients. SARS-CoV-2 is the coronavirus responsible for the Covid-19 pandemic.Based upon these promising results, Bolder BioTechnology intends to file an Investigational New Drug Application with the U.S. Food and Drug Administration ...

Read More
news image

AI

BIOMARIN AND DEEP GENOMICS TO COLLABORATE ON ADVANCING PROGRAMS IDENTIFIED USING ARTIFICIAL INTELLIGENCE

BioMarin | November 18, 2020

BioMarin Pharmaceutical Inc. and Deep Genomics declares that the organizations have gone into a preclinical collaboration that will use Deep Genomics' artificial intelligence drug discovery platform (The AI Workbench) to distinguish oligonucleotide drug applicants in four uncommon sickness signs with high neglected need. Deep Genomics will get an undisclosed forthright installment and is qualified to get improvement achievements as a piece of the coordinated effort. BioMarin will get an elit...

Read More
news image

Medical

SALIPRO BIOTECH OBTAINS GRANTED PATENTS IN THE UNITED STATES AND CHINA FOR DIRECT EXTRACTION OF MEMBRANE PROTEINS AND LIBRARY GENERATION

Salipro Biotech | September 08, 2022

Salipro Biotech AB, a Swedish biotech company with a leading technology platform for the stabilization of membrane proteins for drug development, announced today that its patent entitled "Saposin lipoprotein particles and libraries from crude membranes" has been issued by both the U.S. Patent and Trademark Office and by the China National Intellectual Property Administration. The patents cover the company's novel method of direct extraction of membrane proteins from cells or crude ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us